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Abstract
Type 1 diabetes (T1D) is an autoimmune disease in which insulin-producing beta cells in
pancreatic islets are progressively destroyed. Clinical trials of immunotherapies in recently
diagnosed T1D patients have only transiently and partially impacted the disease course,
suggesting that other approaches are required. Our previous studies have demonstrated
that heparan sulfate (HS), a glycosaminoglycan conventionally expressed in extracellular
matrix, is present at high levels inside normal mouse beta cells. Intracellular HS was shown
to be critical for beta cell survival and protection from oxidative damage. T1D development
in Non-Obese Diabetic (NOD) mice correlated with loss of islet HS and was prevented by
inhibiting HS degradation by the endoglycosidase, heparanase. In this study we investi-
gated the distribution of HS and heparan sulfate proteoglycan (HSPG) core proteins in nor-
mal human islets, a role for HS in human beta cell viability and the clinical relevance of intra-
islet HS and HSPG levels, compared to insulin, in human T1D. In normal human islets, HS
(identified by 10E4mAb) co-localized with insulin but not glucagon and correlated with the
HSPG core proteins for collagen type XVIII (Col18) and syndecan-1 (Sdc1). Insulin-positive
islets of T1D pancreases showed significant loss of HS, Col18 and Sdc1 and heparanase
was strongly expressed by islet-infiltrating leukocytes. Human beta cells cultured with HS
mimetics showed significantly improved survival and protection against hydrogen peroxide-
induced death, suggesting that loss of HS could contribute to beta cell death in T1D. We
conclude that HS depletion in beta cells, possibly due to heparanase produced by insulitis
leukocytes, may function as an important mechanism in the pathogenesis of human T1D.
Our findings raise the possibility that intervention therapy with dual activity HS replacers/
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heparanase inhibitors could help to protect the residual beta cell mass in patients recently
diagnosed with T1D.
Introduction
Type 1 diabetes is an autoimmune disease which destroys the insulin-producing beta cells of
pancreatic islets [1±3]. T lymphocytes have been detected in islet-associated inflammation
(insulitis) strongly supporting a role for T cell-mediated autoimmune responses in the disease
process [4±6]. However, recent clinical trials testing the blockade of T cell activation and func-
tion as well as cytokine-based strategies for immunomodulation in patients with new-onset
type 1 diabetes have resulted in only limited therapeutic benefit, with a slower decline in insu-
lin secretion and a modest impact on insulin requirement and disease progression [1, 7±10].
These outcomes have stimulated other avenues of research to better understand the pathogene-
sis of the disease and to develop more effective intervention strategies. Cadaver donor or archi-
val human pancreas specimens [11, 12] and live donor pancreas and blood specimens [13±16]
have been used to investigate islet-infiltrating leukocytes in insulitis lesions [4, 17, 18], the role
of the extracellular matrix (ECM) in regulating the intra-islet entry of leukocytes into human
islets [19, 20], the modulation of peripheral blood neutrophil levels [15, 16] and the contribution
of enteroviral infection of beta cells as a potential trigger for leukocyte recruitment [21, 22]. In
addition, it has become increasingly evident that the residual beta cell mass at diagnosis is much
more significant than previously estimated [3, 23], highlighting the potential for therapeutic
strategies to safeguard these viable beta cells and preserve their function [7, 9]. To this end, ther-
apeutic interventions have largely focused on directly suppressing the autoimmune response in
T1D and little attention has been devoted to better understanding the intrinsic requirements for
beta cell survival. In this study we investigated a role for intracellular heparan sulfate (HS), a sul-
fated glycosaminoglycan, as a requirement for the survival of human beta cells and as a marker
of beta cell damage in human T1D, identifying HS preservation as a possible novel therapeutic
strategy for beta cell protection and preventing T1D progression.
HS is a linear polysaccharide composed of repeating dissacharides (consisting of glucos-
amine and uronic acid) and is covalently attached to core proteins, forming heparan sulfate
proteoglycans (HSPGs). HSPGs are classified by their specific core protein and are conven-
tionally localized in extracellular matrix (ECM; e.g., collagen type XVIII (Col18), agrin) and
on the surface of cells (e.g., syndecans, glypicans). Their HS side chains act as adhesion mole-
cules and as reservoirs for chemokines, cytokines and growth factors [24, 25]. Perlecan, a large
HSPG, is found in basement membranes (BMs), including the peri-islet BM, and helps to pre-
vent cell invasion [26]. We have previously identified the unusual localization of HS and the
HSPGs Col18 and syndecan-1 (Sdc1), inside mouse beta cells [27, 28]. HS in beta cells has
been shown to have diverse functions which are regulated largely by the HS sulfation pattern
and related, in some instances, to specific HSPG core proteins. Of significance, highly sulfated
HS was reported to be essential for the survival of primary beta cells and to provide protection
from oxidative damage [27]. In support, desulfation of HS in the rat INS1 beta cell line
increased the sensitivity of the beta cells to hydrogen peroxide-induced damage [29]. Further-
more, by depleting beta cell HS in mice, Takahashi et al demonstrated a critical role for HS in
islet development and beta cell function [30]. Specifically, beta cell HS, 3-O-sulfation of HS
and the HSPG syndecan-4 have been shown to play important roles in the secretion of insulin
by mouse beta cells or beta cell lines [30±32]. However, little is known about HS and its roles
in human beta cells.
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HS is more widely recognized for its extracellular distribution in the ECM and basement
membranes, regulating in particular, cell invasion, cell migration and inflammation [25, 33±
35]. Heparanase, the only mammalian endoglycosidase, degrades HS and plays a critical role
in permitting cells, including leukocytes, to traverse basement membranes and to migrate into
underlying tissues [25]. Heparanase is produced by various leukocytes and has also been
shown to be expressed by endothelial cells and/or susceptible tissues in acute and chronic
inflammatory disease models, e.g., acute pancreatitis, ulcerative colitis, glomerulonephritis
[36±38], as well as in diabetes-related complications e.g., nephropathy and retinopathy [39±
41]. We have previously found that the unusually high levels of HS in islet beta cells and the
localisation of the HSPG perlecan in the peri-islet basement membrane render islet beta cells
particularly vulnerable to heparanase-mediated damage. During T1D development in non-
obese diabetic (NOD) female mice, islet HS progressively declined and disruption of the peri-
islet BM correlated with the expression of the HS-degrading enzyme heparanase by infiltrating
leukocytes in the insulitis lesions [26, 27]. Significantly, treatment of NODmice with the
heparanase inhibitor/HS replacer PI-88, reduced the incidence of diabetes by ~50% and pre-
served intra-islet HS [27]. These observations provide strong support for heparanase-mediated
depletion of islet HS as an important mechanism in the pathogenesis of T1D [42].
In this study we examined the clinical relevance of HS for human beta cell survival and as a
target during T1D disease development in humans. Our findings confirm the presence of high
levels of intra-islet HS and HSPG core proteins in normal human islets and support a unique
role for HS in human beta cell survival; furthermore, we demonstrate that beta cell HS is lost
before insulin in human T1D and is a sensitive marker of disease progression.
Methods
Human samples
Paraffin sections of formalin-fixed human pancreas specimens from non-diabetic organ
donors (n = 8), T1D donors with insulin-positive (Ins+) islets (n = 8) and T1D donors with
insulin-negative islets (n = 10) were obtained from the JDRF Network for Pancreas Organ
Donors with Diabetes (nPOD) [11]. nPOD pancreases were procured with consent and under
the University of Florida IRB review; all nPOD human pancreas samples were de-identified
and the donor T1D/non-T1D status was accessed anonymously. T1D pancreases with insulin-
containing islets (#6046, #6052, #6069, #6070, #6084, #6198, #6209, #6212) were obtained from
5±22.9 year-old donors at 0.25±8 years after diagnosis. The control donors (#6012, #6075,
#6094, #6096, #6102, #6104, #6129, #6134) were 2.9±68 years of age. Isolated human islets
were obtained from the TomMandel Islet Transplant Program at St Vincent's Institute of
Medical Research (SVI), Melbourne (Australia) and from the Integrated Islet Distribution Pro-
gram (City of Hope National Medical Center, Duarte, CA; http://www.iidp.coh.org). Docu-
mented consent was provided for the use of human islets for research, the donors were de-
identified and batches of isolated human islets together with analytical data were labeled with a
SVI number or Lot number, respectively, to ensure the anonymity of the donor. These proce-
dures were carried out with review and approval by appropriate regulatory authorities. Islets
with 86.8±7.9% (n = 10) purity were used at 1±7 days post-isolation. The shipping time varied
between ~7 hours (national) to ~35 hours (international). Formalin-fixed isolated human islets
were also provided by the Department of Medicine, Technical University of Dresden (Dres-
den, Germany). Research using isolated human islets and pancreas specimens was approved
by the Australian National University (ANU) Human Research Ethics Committee (protocols
2008/536 and 2014/689).
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Preparation and culture of isolated human islet cells
Isolated human islets were dispersed into single cells using Accutase (Milllipore, Temecula,
CA), ~1500±2000 islet equivalents/ml (https://dx.doi.org/10.17504/protocols.io.kwwcxfe).
2.0±6.5 x 104 islet cells were transferred to individual wells of a 96 well culture plate (CELL-
STAR, Greiner Bio-one, Frickenhausen, Germany) for immediate staining for flow cytometry
analysis or for culture in RPMI 1640 medium (Sigma-Aldrich, St Louis, MO) supplemented
with 10% fetal calf serum (Sigma-Aldrich) and antibiotics (penicillin G (0.06 mg/ml; MP Bio-
medicals, Santa Ana, CA) /streptomycin (0.10 mg/ml; Sigma) /neomycin (0.10 mg/ml;
Sigma)) [27] prior to staining.
Culture of isolated human islet cells with HSmimetics
Isolated human islet cells were cultured in the presence (50 µg/ml) or absence of the HS
mimetics heparin (a highly sulfated HS analogue from porcine intestinal mucosa; Celsus Labo-
ratories, Cincinnati, OH) or FITC-heparin (see Supporting Information, S1 Appendix), BT548
(a glycol split low molecular weight heparin (LMWH; 3 kDa) lacking anti-coagulant activity
[43, 44]) or PI-88 (phosphomannopentaose sulfate; Progen Pharmaceuticals Limited, Bris-
bane, Australia) [45] for 2 days in 5% CO2, 95% air at 37ÊC[27]. PI-88 is structurally distinct
from BT548. BT548 is a LMWH derived from limited nitrous acid treated, glycol split (period-
ate-treated) heparin isolated from porcine intestinal mucosa and consists of a mixture of sul-
fated oligosaccharides containing uronic acid and glucosamine residues. In contrast, PI-88 is a
mixture of highly sulfated monophosphorylated mannose oligosaccharides (predominantly
phosphomannopentaose sulfate and phosphomannotetraose sulfate), derived from the extra-
cellular phoshomannan of the yeast Pichia holstii [45]. In some studies islet cells were acutely
treated with 30% H2O2 (Chem-Supply, Gillman, Australia) as a source of reactive oxygen spe-
cies (ROS) for 5 min on day 0 or after culture for 2 days with/without HS mimetics.
Flow cytometry
Beta cells were identified by staining with Newport Green (NG; 10 µmol/L; Invitrogen, Molec-
ular Probes, Eugene, OR), a fluorescent probe that detects zinc in the insulin granules of beta
cells [46]. Damaged and dying islet cells were assessed using 7-Aminoactinomycin (7AAD,
10 µg/ml; Life Technologies, Eugene, OR) or by Sytox green (31.25 nmol/L; Invitrogen, Molec-
ular Probes) uptake (https://dx.doi.org/10.17504/protocols.io.kwwcxfe) [27]. For intracellular
staining, isolated islet cells were fixed in 2% paraformaldehyde (Sigma-Aldrich) and permeabi-
lized using 0.3% saponin (Sigma-Aldrich). The cells were stained with 10E4 mouse anti-
human HS mAb (10E4, 1/50; Seikagaku, Tokyo, Japan or US Biological/Amsbio, Abingdon,
UK), mouse anti-mouse Col18 mAb (1/50; Santa Cruz Biotechnol., Santa Cruz, USA) or the
corresponding isotype control Ig (mouse IgMκ or IgG2bκ; BD Biosciences, San Jose, CA) fol-
lowed by goat anti-mouse Ig-R-phycoerythrin (1/100; Southern Biotech, Birmingham, AL)
(https://dx.doi.org/10.17504/protocols.io.kwzcxf6) [27]. The geometric mean fluorescence
ratio (GMFR) was calculated by dividing the geometric mean fluorescence intensity (GMFI) of
cells stained with primary mAb by the GMFI obtained with the relevant isotype control Ig
[27]. Cells were analyzed using a BD LSRI flow cytometer and CellQuest™ Pro software (ver-
sion 6.0; BD Biosciences).
Histology and immunohistochemistry
For quantitative analyses of HS, HSPGs, insulin and glucagon localization in human islets, par-
affin sections (4 µm thickness) of nPOD human pancreases and isolated human islets fixed in
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10% neutral-buffered formalin were stained with hematoxylin and eosin (H&E) or by immu-
nohistochemistry. Antigen retrieval for HS and Col18 was performed using 0.05% pronase
(Calbiochem, Japan) [27, 28], whereas heat/citrate buffer (pH 6) was used for Sdc1 and hepara-
nase [27, 28]. HS and HSPG core proteins were detected immunohistochemically using 10E4
anti-HS (1/5-1/10; https://dx.doi.org/10.17504/protocols.io.kvzcw76), anti-Col18 (1/100;
https://dx.doi.org/10.17504/protocols.io.kvzcw76) and rat anti-mouse Sdc1 (CD138, 1/10; BD
Biosciences) (https://dx.doi.org/10.17504/protocols.io.kv3cw8n) mAbs, with horseradish per-
oxidase-conjugated rabbit anti-mouse or anti-rat Ig (Dako, Carpinteria, USA). Heparanase
was localized using the HP130 mouse anti-human heparanase mAb (1/5; Insight Biopharma-
ceuticals, Rehovot, Israel), biotinylated anti-mouse IgG (1/250) and avidin-biotin-complex
(ABC reagent; PK-2200, Vector Laboratories, Burlingame, CA) (https://dx.doi.org/10.17504/
protocols.io.kv4cw8w). Background staining was checked using the corresponding isotype
control Ig and human pancreatic lymph node (PLN) was used as a positive control. Insulin
and glucagon were detected using mouse anti-insulin (ascites; 1/250) or mouse anti-glucagon
(ascites; 1/500) mAbs (Sigma-Aldrich) and biotinylated anti-mouse IgG/ABC reagent (https://
dx.doi.org/10.17504/protocols.io.kv6cw9e). 3-amino-9-ethylcarbazole (AEC; Sigma-Aldrich)
was used as the chromogen. Specimens were de-identified prior to morphometric analysis.
Image J software with color deconvolution plugin was used for the quantitative analysis of the
% of islet area stained [27, 28] in 7±10 islets/donor pancreas.
Immunofluorescence microscopy
For colocalization studies, paraffin sections were treated with 0.05% pronase for antigen
retrieval, blocked with 2% bovine serum albumin (BSA; Sigma)/phosphate buffered saline
(PBS), incubated overnight (4ÊC) with 10E4 (anti-HS) mAb (1/10), washed and stained with
AlexaFluor 488-goat anti-mouse IgM (Thermo Fisher, Rockford, IL, USA). The same sections
were washed, incubated with rabbit anti-human glucagon IgG (Abcam, Cambridge, UK) or
guinea-pig anti-insulin Ig (Dako, Santa Clara, CA, USA), washed and stained with Alexafluor
568-donkey anti-rabbit IgG or AlexaFluor 568-goat anti-guinea-pig IgG (Thermo Fisher)
(https://dx.doi.org/10.17504/protocols.io.kvycw7w). The specificity of HS staining was
checked on serial sections using IgMκ isotype control (BD Biosciences), instead of 10E4 mAb,
together with anti-glucagon or anti-insulin antibody. Nuclei were stained with DAPI (0.2 µg/
ml; Sigma). Sections were imaged using an automated Axio Observer inverted fluorescence
microscope (Zeiss; GoÈttingen, Germany). Merged images were prepared using ZEN (version
2.3) software (Zeiss).
Statistical analyses
For comparisons between groups in immunohistochemical analyses, the 2-tailed, unpaired
Student's t test and Mann-Whitney test were used. One-way ANOVAwith Bonferroni Multi-
ple Comparisons test, non-parametric ANOVA (Kruskal-Wallis test) with Dunn's Multiple
Comparisons test, unpaired Student's t-test or Mann-Whitney test were used to analyse flow
cytometry data. P<0.05 was considered to be statistically significant.
Results
Distribution of intra-islet HS and HSPG core proteins in normal and
diabetic human pancreas
Immunohistochemistry revealed widespread intra-islet localization of HS as well as Col18 and
Sdc1 core proteins in normal human pancreas, correlating with the distribution of the insulin
Human islet heparan sulfate
PLOSONE | https://doi.org/10.1371/journal.pone.0191360 February 7, 2018 5 / 18
staining (Fig 1A±1E). Similarly, in T1D pancreases with Ins+ islets, staining for Col18, Sdc1
and HS correlated with residual insulin-containing beta cells (Fig 1F±1J), a finding which was
also observed in islets with insulitis (Fig 2). Immunofluorescence microscopy demonstrated
that HS (identified by 10E4 mAb) co-localized with insulin (Fig 3A±3D) and not glucagon (Fig
3E±3H) in normal islets. Little or no staining for HS was observed in pseudoatrophic (insulin-
Fig 1. Intra-islet HS and HSPG core proteins in human pancreases correlate with insulin-positive beta cells.
Immunohistochemical analyses of (A-E) a normal human pancreas (nPOD #6134) and (F-J) a pancreas with insulin-
containing (Ins+) islets from a donor with T1D (nPOD #6084, 4 years post-T1D onset) show the distribution of (B,G)
insulin-positive beta cells, intra-islet (C,H) HS, (D,I) Col18 core protein and (E,J) Sdc1 core protein. (A,F), H&E. Scale
bar = 100 µm.
https://doi.org/10.1371/journal.pone.0191360.g001
Human islet heparan sulfate
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negative, glucagon-positive) T1D islets (data not shown). Morphometric analyses of normal
pancreas specimens revealed that the % islet area stained for HS, Col18 and Sdc1 was 21.2
±0.7% (Fig 4A), 33.1±1.2% (Fig 4B), 23.0±1.1% (Fig 4C), respectively. Beta cells and alpha cells
were identified by the insulin-positive islet area (32.9±1.3%; Fig 4D) and glucagon-positive
area of staining (11.5±0.8%; Fig 4E), respectively (S1 Table). In Ins+ T1D pancreases, the %
area of insulin staining in the remaining islet tissue was 86% of normal islets (Fig 4D and S1
Table). However, the area stained for HS, Col18 and Sdc1 was significantly reduced to 41%
(P<0.0001), 55% (P<0.0001) and 42% (P<0.0001) of normal islets, respectively (Fig 4A±4C
and S1 Table). In contrast, the glucagon-positive islet area increased 1.5-fold (Fig 4E and S1
Fig 2. Immunohistochemical localization of intra-islet HS and HSPG core proteins in Ins+ T1D human pancreas
with insulitis. Insulitis in the pancreas of nPOD #6070 (7 years post-T1D onset) (A) is adjacent to (B) residual insulin-
positive beta cells which show staining for (C) Col18 and (D) Sdc1 core proteins but (E) little HS (). (F) Glucagon
staining is distinct from HSPGs (C,D) and HS (E). (A) H&E. Scale bar = 100 µm.
https://doi.org/10.1371/journal.pone.0191360.g002
Fig 3. Intra-islet HS colocalizes with insulin not glucagon staining in normal human pancreas. Immunofluorescence staining of (A)
insulin (INS), (B,F) HS and (E) glucagon (GLUC), in normal human pancreas (nPOD #6134). Nuclei were stained with DAPI (D,H). (A)
anti-insulin Ab; (B,F) 10E4 anti-HS mAb; (E) anti-glucagon Ab; (C,G) merged (excluding DAPI); (D,H) merged (including DAPI). Scale
bar = 20 µm.
https://doi.org/10.1371/journal.pone.0191360.g003
Human islet heparan sulfate
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Table). These data indicate that HS and HSPG core proteins were localized in the beta cells of
normal human islets and that the loss of intra-islet HS during diabetes progression preceded
the decline in insulin content.
Fig 4. Intra-islet HS and HSPG core protein levels decline in Ins+ islets in human T1D.Morphometric analysis of
the (A) HS-positive, (B) Col18-positive, (C) Sdc1-positive, (D) insulin-positive and (E) glucagon-positive islet area in
normal human pancreases (black bars) and Ins+ T1D human pancreases (open bars). Data shows mean ± SEM;
n = 6±8pancreases (n = 56±80 islets) examined/group for normal controls and n = 6±8pancreases (n = 52±66 islets)/
group for Ins+ diabetic donors, except for analyses of Sdc1 where n = 4±5pancreases (n = 40±42 islets) were
examined/group. Significance was determined using unpaired Student's t test,  = P<0.0001,  = P = 0.0217 and
Mann-Whitney test,  P = 0.0025.
https://doi.org/10.1371/journal.pone.0191360.g004
Fig 5. HS and HSPG core protein are localized inside isolated human islet beta cells. Immunofluorescence staining of 1
day-cultured isolated human islets show co-localization of (A) insulin (INS) and (B) HS. Nuclei were stained with DAPI
(D). (A) anti-insulin Ab; (B) 10E4 anti-HS mAb; (C) merged (excluding DAPI); (D) merged (including DAPI). Scale
bar = 20 µm. (E) Representative single color flow cytometry histograms of freshly isolated human islet cells (89% were NG-
positive beta cells) show staining for intracellular HS (pink solid line) and Col18 (blue solid line) compared to background
staining with corresponding isotype control Ig (dotted lines) and the autofluorescence of unstained cells (black solid line).
https://doi.org/10.1371/journal.pone.0191360.g005
Human islet heparan sulfate
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HS in isolated normal islets and beta cells
In contrast to islets in normal human pancreas, immunofluorescence microscopy showed that
insulin-positive staining in isolated normal human islets correlated with a wide variation in
HS staining (Fig 5A±5D). These findings are consistent with partial loss of intra-islet HS
occurring during the isolation of human islets, like isolated mouse islets [27, 28]. Flow cytome-
try analysis of dispersed islet cells revealed that levels of intracellular HS (mean GMFR = 3.6±
0.3; n = 8 experiments) and Col18 (mean GMFR = 15.1±2.6; n = 7 experiments) were 2.6-fold
(P = 0.0003) and 7.2-fold (P = 0.0012) higher, respectively, than on the surface of islet cells (Fig
5E, Table 1 and S2 Table). NG-positive staining revealed that 80.5±2.9% of human islet cells
were beta cells (Fig 6A and S3 Table); in separate flow cytometry studies, 21%-24% of islet cells
stained positively for intracellular glucagon i.e., alpha cells (data not shown). These findings
further support the intracellular localization of HS and Col18 core protein inside human beta
cells and suggest that HS levels in human beta cells decline during their isolation in vitro.
Protection of human beta cell viability by HS replacers
Flow cytometry analyses showed no significant change in the beta cell population after culture
of human islet cells for 2 days (84.1±3.3%; Fig 6A and S3 Table). On day 0, 25.2±3.6% of the
total islet cell population were damaged or non-viable beta cells (NG-positive, 7AAD-positive;
Fig 6B and S4 Table) and 55.3±2.0% were viable beta cells (NG-positive, 7AAD-negative; Fig
6C and S4 Table). Culture of the beta cells with the HS mimetics heparin, PI-88 and BT548 sig-
nificantly improved beta cell viability by ~1.6-fold (P<0.001; Fig 6C and S4 Table) and signifi-
cantly reduced the proportion of damaged/non-viable beta cells from 32.1±3.6% to 9.3±0.5%
(P<0.01), 8.0±0.5% (P<0.001) and 10.1±0.8% (P<0.05), respectively (Fig 6B, S1 Fig and S4
Table). The minor population of NG-negative, 7AAD-positive cells also improved their sur-
vival after co-culture with HS mimetics (S2 Fig and S4 Table), suggesting that they could repre-
sent insulin-depleted beta cells. Beta cells cultured with heparin showed no detectable increase
in intracellular HS (Table 1) due to the specificity of the 10E4 mAb for HS and not heparin
[47]. In addition, human beta cells cultured with FITC-heparin for 1 day showed intracellular
uptake of fluorescent heparin by confocal microscopy and protection from dying (S3 Fig).
Together these findings indicate that exogenous HS mimetics promote the survival of human
beta cells by acting as replacers for intracellular HS lost during islet/beta cell isolation.
Table 1. Expression of HS and Col18 in freshly isolated human beta cells and after culture in the absence or presence of heparin.
HSa Col18a
Treatmentb Intracellular Cell Surface Intracellular Cell Surface
Control d0c 3.6±0.3 1.4±0.1 15.1±2.6 #2.1±0.2
Control d2d 4.0±0.4 2.5±0.3 9.5±1.4 2.8±0.4
Heparin d2e 3.3±0.4 1.8±0.2 11.5±1.7 #4.3±1.0
a Flow cytometry GMFI data (see Methods) for intracellular (IC) and cell surface (CS) staining presented as mean ± SEM, n = 5±8 independent experiments.
b Control d0, freshly dispersed control human islet cells were 83.7±9.4% NG-positive beta cells (n = 6 experiments); Control d2, 2 day cultured control human islet cells;
Heparin d2, human isolated islet cells cultured for 2 days with 50 µg/ml heparin.
P<0.01, One-way ANOVAwith Bonferroni Multiple Comparison test
#P<0.05, Non-parametric One-way ANOVA (Kruskal-Wallis test) with Dunn's Multiple Comparisons test
c HS, IC versus CS, P = 0.0003, Mann-Whitney test; Col18, IC versus CS, P = 0.0012, Mann-Whitney test test
d HS, IC versus CS, P = 0.0125, Unpaired t-test; Col18, IC versus CS, P = 0.0025, Mann-Whitney test
e HS, IC versus CS, P = 0.0109, Mann-Whitney test; Col18, IC versus CS, P = 0.0089, Unpaired t-test
https://doi.org/10.1371/journal.pone.0191360.t001
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HS replacement protects human beta cells against oxidative damage
The improved viability of human islet cells after HS replacement was also observed by flow
cytometry analysis of Sytox green uptake (6.2±10.1% cell damage/death versus 40.2% for con-
trols; Fig 7 and S5 Table). Freshly isolated human beta cells treated with hydrogen peroxide
(source of reactive oxygen species (ROS)), showed a 2-fold increase in cell death, marked by
an increase in the proportion of Sytox green-positive cells from 41.3±2.2% to 80.9±2.2% (Fig 7
and S5 Table). In contrast, culture with heparin, PI-88 or BT548 for 2 days and subsequent
treatment with hydrogen peroxide substantially decreased the Sytox green-positive non-viable
human beta cells to 13.8%-18.0% of total cells, compared to 49.1% for corresponding controls
(Fig 7 and S5 Table). Beta cell survival after exposure to hydrogen peroxide was significantly
improved after HS replacement with PI-88 (P<0.05).
Heparanase is expressed by islet-infiltrating leukocytes in human diabetes
Consistent with a significant decline in the HS content of Ins+ diabetic human islets, islet-infil-
trating leukocytes (Fig 8A±8C) showed intense cell surface expression of the HS-degrading
endoglycosidase heparanase. In comparison, islet cells in normal and diabetic pancreases
showed negligible or weak expression, respectively (Fig 8D and 8G). These findings suggest
that like NODmice [27], HS in human beta cells may be degraded by heparanase produced by
islet-infiltrating leukocytes.
Fig 6. HS optimizes human beta cell survival in vitro. Flow cytometry analyses of the viability of freshly isolated
human islet cells (Con) on day 0 and after culture for 2 days with or without heparin, PI-88 or BT548 at 50 µg/ml.
(A-C) Islet cells were stained with Newport Green (NG) to identify beta cells and with 7AAD (B and C) to label non-
viable cells; NG+ve, 7AAD-ve staining identified viable beta cells (C). Con, control; Hep, Heparin; BT548, chemically
modified LMWH. Data (% islet cells) shows mean ± SEM; n = 8±10 independent experiments and significance was
measured by non-parametric ANOVA (Kruskal-Wallis test) with Dunn's Multiple Comparisons test.  P<0.001,
P<0.01, P<0.05.
https://doi.org/10.1371/journal.pone.0191360.g006
Fig 7. HSmimetics protect human beta cells from oxidative damage. Flow cytometric analyses of isolated human
islet cells cultured with or without HS mimetics for 2 days and then treated acutely with hydrogen peroxide. Islet cell
death/damage was measured by Sytox green fluorescence. Con, control; Hep, Heparin; BT548, chemically modified
LMWH. Data shows mean ± SEM; n = 11±12 independent experiments. Con d0 versus Con d0 + hydrogen peroxide,
Unpaired t-test, P<0.0001; Con d2 + hydrogen peroxide versus PI-88 d2 + hydrogen peroxide, non-parametric
ANOVAwith Dunn's Multiple Comparisons test,  P<0.05.
https://doi.org/10.1371/journal.pone.0191360.g007
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Discussion
This study demonstrates that HS (identified by 10E4 mAb) and the HSPG core proteins for
Col18 and Sdc1 are strongly expressed in normal human islets, and importantly, are localized
inside beta cells. Our findings support a preliminary report of the immunolocalization of
highly sulfated HS in insulin-containing beta cells of a single human pancreas [29]. Consistent
with the finding of less-sulfated HS in alpha cells [29], we confirm that highly sulfated HS (rec-
ognized by 10E4 mAb) is selectively expressed in normal human beta cells and is absent in
alpha cells. We previously reported that the uptake of highly sulfated but not under-sulfated
HS protected mouse beta cells against dying in culture or from oxidant-induced death [27].
Using highly sulfated HS mimetics as HS replacers, we have now confirmed that intracellular
HS plays a critical role in the viability of human beta cells. This key function underpins the
unique localization of highly sulfated HS in healthy normal beta cells.
From a mechanistic standpoint, we propose that intracellular HS normally preserves beta
cell viability in situ by acting as a constitutive nonenzymatic antioxidant, providing immediate
protection from damaging reactive chemical species (e.g., ROS) generated during normal
metabolism [27]. Our mouse studies have revealed, however, that HS loss during islet isolation
is due, at least in part, to the generation of excessive levels of ROS, which can depolymerize HS
[27, 28, 48, 49]. Furthermore, we have shown that islet HS is not readily repaired by de novo
synthesis in vitro [28]. In human beta cells, the expression of ROS scavenging enzymes (e.g.,
superoxide dismutase 2 (SOD2)) can be induced [50], a process that may represent an alternate
Fig 8. Heparanase is expressed by human insulitis leukocytes. (A) An islet (I) with insulitis in nPOD pancreas #6084
(4 years post-T1D onset) shows (B) leukocytes strongly expressing heparanase (Hpse) and (C) glucagon staining.
Normal human islet cells (nPOD #6012) (D) showed negligible heparanase expression compared to pancreatic lymph
node (PLN) from the same donor (E). Islet cells in Ins+ T1D pancreas (nPOD #6070) weakly expressed heparanase
(arrowhead), compared to nearby infiltrating leukocytes (arrow) (G) and host PLN (H). Background staining with
isotype control Ig was absent in PLNs (F and I). (A) H&E; (B, D, E, G, H) anti-Hpse HP130 mAb; (C) anti-glucagon
mAb; (F, I) mouse IgM. Scale bar = 100 µm.
https://doi.org/10.1371/journal.pone.0191360.g008
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mechanism for neutralizing elevated levels of ROS during culture. We observed that in vitro,
HS replacement in human beta cells better preserves their survival and is more protective
against oxidative damage than alternative mechanisms that operate or are induced in control
beta cells (see Fig 7). While the subcellular sites of endogenous HS and HSPGs in beta cells
have yet to be defined, the localization of FITC-labelled heparin in the cytoplasm (S3C Fig)
correlated with improved viability (S3B Fig). These findings further suggest that preserving
islet HS during human islet isolation could improve the viability of transplanted islets in the
peri-transplant period [51, 52], and in conjunction with optimal combinations of anti-rejec-
tion strategies [51±53] could improve islet graft outcomes for T1D patients.
We investigated whether the depletion of beta cell HS correlates with the progression of
T1D in humans, as in NODmice [27]. We found that the HS and HSPG core protein profiles
of insulin-positive islets showed a profound decline in the pancreas of organ donors with T1D,
compared to non-diabetic islets. Based on the role for HS in human beta cell survival and the
striking protection from ROS in vitro, we postulate that the loss of HS observed in T1D pancre-
ases primes beta cells for oxidative damage and impairs their viability. Supporting this notion,
there is increasing evidence of beta cell dysfunction in T1D [54] and this likely precedes auto-
immune-mediated beta cell death. Such changes in beta cell viability/function could also
impact nearby alpha cells, possibly leading to their expansion (see Fig 4E) or redistribution
within the islets, as reported previously in a mouse model of diabetes [55]. Overall, our find-
ings strongly suggest that the level of intracellular HS represents a robust marker of the viabil-
ity of residual beta cells during T1D progression.
Significantly, in human T1D, we observed that beta cells lose HS before insulin. We also
found that ~15% of the total Ins+ islets showed insulitis, confirming the low frequency
reported by other studies [11, 56]. In both NODmice and man, immunofluorescence micros-
copy has demonstrated that infiltrating leukocytes destroy the peri-islet BM at the time they
invade the islet tissue [20, 26]. Korpos et al reported that human leukocytes express ECM-
degrading proteases (cathepsins) that solubilize the islet BM [20]. Importantly, in this study,
we provide evidence for strong expression of cell surface heparanase, a HS-degrading enzyme,
by human insulitis leukocytes. It should be noted, however, that although similar heparanase
staining was observed for lymph node leukocytes, the anti-heparanase antibody used for
immunohistochemistry did not distinguish between inactive (latent or proenzyme) and cata-
lytically active enzyme [27, 34]. As previously found during T1D development in NOD/Lt
mice [27], heparanase produced by insulitis leukocytes plays a critical role in degrading HS in
the islet BM and inside beta cells, rendering the beta cells highly susceptible to oxidant-medi-
ated damage and death. Additionally, leukocyte-derived proteases could contribute to the
destruction of HSPG core proteins in beta cells, a process that may require initial cleavage of
their HS chains. It is possible that the relative contribution of destructive mediators by differ-
ent types of leukocytes could contribute to the age-related heterogeneity of the pathogenesis of
T1D [2, 18, 57]. If multiple mechanisms operate, combined therapeutic strategies are likely to
be required for impeding disease progression. Moreover, where islet HS is lost in the absence
of insulitis, beta cell HS could potentially be degraded by heparanase produced by the beta
cells themselves or possibly by high levels of endogenous ROS. Interestingly, in acute pancrea-
titis in mice and colitis in mice and humans, heparanase expression is strongly induced or ele-
vated in pancreatic acinar cells [37] and gut epithelial cells [38], respectively, and contributes
to local inflammation. The differences between these findings and our T1D study could be
related to islet tissue-specific properties, differences in the relative contribution of adaptive
and innate immune responses and/or to the different anti-heparanase antibodies (recognizing
latent and/or catalytically active enzyme) and antigen retrieval methods used. Of significance
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for human T1D, we identify intracellular HS in beta cells as a requirement for beta cell viability
and as a target for early destruction during disease progression.
We propose that at the time of T1D diagnosis, the survival of residual beta cells could
potentially be maintained by HS replacement and/or HS preservation via blockade of hepara-
nase activity. Importantly, HS replacers such as heparin, PI-88 and BT548 profoundly inhibit
the catalytic activity of recombinant human heparanase (S4 Fig), suggesting that as dual activ-
ity drugs, they could represent a new class of therapeutic for restoring beta cell HS and blunt-
ing or preventing the progression of T1D. In summary, intracellular HS plays an important
role in the viability of human beta cells. This study shows that HS levels are a sensitive marker
of beta cell health (high HS) and deterioration (low HS) during T1D progression and suggest
that HS preservation therapy could represent a novel aid for beta cell rescue.
Supporting information
S1 Appendix. Methods for supporting information.
(DOCX)
S1 Fig. HS replacement using HSmimetics improves the viability of human beta cells. Rep-
resentative flow cytometric data shows the viability of control human beta cells on day 0 (top
panel) and day 2 (bottom panel) after staining with Newport Green (NG) and 7AAD (i.e., NG
+ve, 7AAD-ve) and a striking > 2-fold improvement in beta cell viability (upper left quadrant;
bottom panel) after culture with 50 µg/ml HS mimetic (heparin, PI-88, or BT548 (chemically
modified LMWH)) for 2 days.
(TIF)
S2 Fig. HS replacement improves insulin-negative human islet cell survival in vitro. Flow
cytometry analyses of islet cell viability following Newport Green (NG) and 7AAD staining of
human islet cells cultured for 2 days with HS mimetics heparin, PI-88 or BT548 at 50 µg/ml
(from Fig 6 and S4 Table) shows (A) a 6.6±8.5-fold decrease in NG-ve7AAD+ve islet cells and
(B) no significant change in NG-ve7AAD-ve islet cells i.e., viable non-beta cells. The minor
population of NG-ve7AAD+ve control cells at d0 (Con, d0) may represent insulin-depleted
beta cells which are rescued by HS reconstitution during culture for 2 days with HS replacers.
Con, control; Hep, Heparin; BT548, chemically modified LMWH. Data (% islet cells) shows
mean ± SEM; n = 8±10 independent experiments. Significance was analyzed by non-paramet-
ric ANOVA (Kruskal-Wallis Test) with Dunn's Multiple Comparisons test,  = P<0.01,  =
P<0.05.
(TIF)
S3 Fig. Uptake of FITC-heparin by cultured human beta cells correlates with improved via-
bility.Human beta cells cultured for 1 day (A) without or (B) with 50 µg/ml FITC-heparin
were stained with 7AAD and examined by flow cytometry to determine the viability of control
and FITC-heparin+ve beta cells. Percentage of total cells is shown in the quadrants. (C) In par-
allel, confocal microscopy of 1 day-cultured beta cells (from B), confirmed the intracellular
uptake of FITC-heparin (green fluorescence) and its accumulation predominantly in the cyto-
plasm. Immunofluorescence staining with DAPI (blue) identifies the nucleus in the isolated
human islet cells.
(TIF)
S4 Fig. Inhibition of human heparanase activity by HS mimetics. The activity of recombi-
nant human heparanase was inhibited by (A) heparin (IC50 = 73.5 ng/ml (5.3 nM)), (B) PI-88
(IC50 = 79.8 ng/ml (33.2 nM)) and (C) BT548 (chemically modified LMWH; IC50 = 29.2 ng/ml
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(9.7 nM)), in a colorimetric assay using Fondaparinux as substrate.
(TIF)
S1 Table. Percentage of islet area stained for HS, HSPGs (Col18 and Sdc1), insulin and glu-
cagon in normal healthy and T1D human pancreases.
(XLSX)
S2 Table. Geometric mean fluorescence ratio values for HS and Col18 expression in
human islet cells.
(XLSX)
S3 Table. Proportion of beta cells in isolated human islet cells ± culture with HS mimetic.
(XLSX)
S4 Table. Viability of human beta cells ± culture with HSmimetic.
(XLSX)
S5 Table. Viability of human islet cells ± culture with HSmimetic and with/without acute
exposure to hydrogen peroxide.
(XLSX)
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